.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP08_Sofosbuvir.Sofosbuvir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP08_Sofosbuvir.Sofosbuvir| name: | Sofosbuvir |
| ATC code: | J05AP08 | route: | oral |
| n-compartments | 2 |
Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus (HCV) NS5B polymerase. It is an antiviral drug used in combination with other direct-acting antivirals for the treatment of chronic hepatitis C infection. It is approved and widely used as part of combination therapies (e.g., with ledipasvir, velpatasvir, or daclatasvir) and has become a key component in HCV treatment regimens.
Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose under fasting conditions.
Li, X, et al., & Ding, Y (2018). Pharmacokinetics, Safety, and Tolerability of the Direct-acting Hepatitis C Antiviral Sofosbuvir in HealthyChineseSubjects. Clinical therapeutics 40(9) 1556–1566. DOI:10.1016/j.clinthera.2018.07.018 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30185395
Panjasawatwong, N, et al., & Cressey, TR (2024). Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment. Antimicrobial agents and chemotherapy 68(7) e0000824–None. DOI:10.1128/aac.00008-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38767383
Jonas, MM, et al., & Schwarz, KB (2024). Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. Journal of pediatric gastroenterology and nutrition 78(6) 1342–1354. DOI:10.1002/jpn3.12045 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38644678